Determining Front-Line Therapeutic Strategy for Metastatic Clear Cell Renal Cell Carcinoma.

ABSTRACT: The therapeutic landscape for metastatic renal cell carcinoma has rapidly evolved over the years, and we are now in an era of combination therapy strategies employing immune checkpoint blockade and anti-angiogenesis targeted therapy. Since 2018, we have gained regulatory approval for four distinct combination therapies, all with survival benefits, and with guideline recommendation for use in the front-line setting. As such, treatment selection has become increasingly complex with a myriad of treatment choices but little high-level head-to-head data to guide treatment selection. Heterogeneity in tumor biology further complicates treatment selection as tumors vary in behavior and treatment responsiveness. Ongoing development of biomarkers will certainly assist in this setting, and validation

SUBMITTER: Zarrabi KK 

PROVIDER: S-EPMC9559659 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature